isradipine ( sandoz pn 200-110 ) , a new dihydropyridine calcium channel antagonist , was evaluated in a randomized , double-blind , placebo-controlled trial for antihypertensive efficacy in 24 patients with essential hypertension .
C0071304
isradipine
C2945601
dihydropyridine calcium